亚洲激情av-99久久久久-在线亚洲欧美-日韩精品小视频-欧美国产精品一区二区三区-国产有码在线-国产毛片久久-欧美一区二区三区在线看-自拍偷拍第3页-欧美在线视频不卡-成人免费淫片aa视频免费-成人午夜短视频-97精品视频在线播放-日本在线播放一区二区三区-欧洲第一毛片

Welcome to Linuo Group!HomeBusiness License
  • CN

  • WeChat

  • Mobile Site

  • Search

力諾資訊

Keyuan Pharma Wins 2025 Forbes China Industry Development Innovative Brand Award

2025.04.02

Shandong Keyuan Pharmaceutical Co., Ltd. has been awarded the 2025 Forbes China Industry Development Innovative Brand Award at the 2025 Forbes China Industry Development Pioneers Selection held in Shanghai on March 22nd, in recognition of its exceptional innovation capabilities and significant industry influence.

The accolade not only represents high recognition of Keyuan Pharma's years of dedicated efforts in the field of chemical APIs and preparations but also stands as a powerful testament to its leapfrog development driven by innovation amid the adjustments in the global industrial landscape.

Jointly initiated by Frost & Sullivan, a world-renowned growth consulting firm, and Forbes China Group, the 2025 Forbes China Industry Development Pioneers Selection aims to identify outstanding enterprises and individuals in key sectors such as new energy, AI technology, mass consumption, and biomedicine that are driving industry transformation with an innovative spirit. Keyuan Pharma's success in standing out this time underscores its prominent position in the chemical drug sector.

Founded in 2004, Keyuan Pharmaceutical has focused on the R&D, production, and sales of chemical APIs and preparations. It has established three core product lines: anti-diabetic, cardiovascular, and anesthetic drugs, and ranks as a backbone enterprise in the field of chemical synthetic drugs in Shandong Province.

Innovation is the core driving force behind Keyuan Pharma's development. The company has continuously increased its R&D investment, actively explored cutting-edge technologies, and improved its innovation system. Recently, Keyuan Pharma obtained the utility model patent authorization for "a raw material preliminary processing and drying device for metformin hydrochloride processing," marking the fourth patent authorization it has received this year. A series of patent achievements have provided solid support for improving product quality, enhancing production efficiency, and controlling costs, helping the company gain an edge in the fierce market competition.